



ORIGINAL ARTICLE

Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010



Pao-Yu Chen^{a,b}, Yu-Chung Chuang^{a,b}, Jann-Tay Wang^{a,b},
Wang-Huei Sheng^{a,b}, Chung-Jen Yu^{a,c,d}, Chen-Chen Chu^e,
Po-Ren Hsueh^{a,f}, Shan-Chwen Chang^{a,b,c}, Yee-Chun Chen^{a,b,c,*}

^a Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

^b Center for Infection Control, National Taiwan University Hospital, Taipei, Taiwan

^c Department of Medicine, National Taiwan University, College of Medicine, Taipei, Taiwan

^d Medical Information Management Office, National Taiwan University Hospital, Taipei, Taiwan

^e Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan

^f Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

Received 30 April 2012; received in revised form 17 July 2012; accepted 24 August 2012

Available online 11 October 2012

KEYWORDS

Candidemia;
Disease severity;
Epidemiology;
Outcome;
Surveillance

Background: The incidence of candidemia varied between hospitals and different study periods. Few, if any, studies provide the reasons. This hospital-based population study aimed to describe and compare the patient population hospitalized in 2002 and 2010 and determine the disease-specific incidences of candidemia and evaluate the impact of time to initiate anti-fungal therapy on 30-day mortality.

Patients and methods: All patients hospitalized at a 2300-bed teaching hospital in Taiwan in 2002 and 2010 were analyzed for the distribution of age, sex, and type of underlying diseases (maximum of six diagnoses). All patients with blood isolates that were collected in 2002 and 2010 and yielded *Candida* species were included for analysis of the demographic and clinical characteristics, distribution of *Candida* species, length of hospital stay before candidemia, stay in the intensive care units at onset of candidemia, time of initiating systemic antifungal agent, antifungal regimen, and 30-day crude mortality.

Results: In 2010, the hospitalized patients were older ($p < 0.001$), had a higher Charlson Comorbidity Index ($p < 0.001$), and more underlying disease/status, including chronic pulmonary

* Corresponding author. Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10016, Taiwan.

E-mail address: yeechunchen@gmail.com (Y.-C. Chen).

diseases, moderate-to-severe renal diseases, leukemia, lymphoma, and gastrointestinal malignancies ($p < 0.001$) than those seen in 2002. Multivariate analysis identified the following host factors were associated with the occurrence of candidemia in 2010: neonate (adjusted odds ratio [OR], 3.67), 45–64 year (OR, 2.18) and the elderly (OR 2.64), compared with young adult (20–44 year); patients with moderate-to-severe renal diseases (OR, 8.08), leukemia (OR, 4.58) and lymphoma (OR 3.98) and gastrointestinal malignancies (OR 2.80). The incidence density of candidemia was 0.34 and 0.41 per 1000 patient-days in 2002 and 2010, respectively ($p = 0.04$). The majority of characteristics of patients with candidemia and disease-specific incidences of candidemia did not differ between 2002 and 2010. Despite more patients in 2010 receiving antifungal therapy on the same day or 1 day after onset (27.5% vs. 41.2%, respectively, $p = 0.002$), the 30-day mortality remained high (45.9% in 2002 and 44.4% in 2010). Moreover, time to initiate antifungal therapy had no impact on 30-day mortality.

Conclusion: This hospital-based population study demonstrated that the incidence density of candidemia was high and increased in 2010 compared with 2002, which was at least in part due to the increase in the proportion of patients at a higher risk of candidemia. Although antifungal therapy was initiated earlier in 2010, the 30-day mortality remained high.

Copyright © 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.

Introduction

Candida species are important pathogens causing healthcare-associated infections and are associated with high mortality, excess lengths of hospital stay, and medical

costs.^{1,2} A nation-wide surveillance data in Taiwan showed that *Candida* species was the leading pathogens of healthcare-associated infections in the intensive care units (ICUs) of the medical centers and ranked second in regional hospitals in 2010.³ The incidence of bloodstream

Table 1 Characteristics of patients hospitalized at National Taiwan University Hospital in 2002 and 2010

Parameters	2002	2010	<i>p</i> value
Number of acute care beds	2200	2300	—
Total number of admissions	66,763	79,710	—
Total number of patient-days	632,318	691,692	—
Age, y	47.3 ± 23.6	51.2 ± 22.9	<0.001
Sex, male (%)	34,514 (54.58)	39,669 (57.35)	<0.001
Charlson Comorbidity Index	2.10 ± 3.45	3.18 ± 4.33	<0.001
Underlying disease/status, <i>n</i> (%)			
Congestive heart failure	1264 (18.93)	2595 (32.56)	<0.001
Cerebrovascular diseases	3230 (48.38)	3682 (46.19)	0.04
Chronic pulmonary diseases	2629 (39.38)	3372 (42.30)	0.005
Connective tissue diseases	828 (12.40)	2002 (25.12)	<0.001
Moderate-to-severe liver diseases	4076 (61.05)	3302 (41.43)	<0.001
Moderate-to-severe renal diseases	3568 (53.44)	3063 (38.43)	<0.001
Diabetes mellitus without end organ damage	5447 (81.59)	10,530 (132.10)	<0.001
Diabetes mellitus with end organ damage	918 (13.75)	1177 (14.77)	0.10
Any tumor ^a	13,330 (199.66)	26,312 (330.10)	<0.001
Lymphoma	865 (12.96)	1776 (22.28)	<0.001
Leukemia	1186 (17.76)	1779 (22.32)	<0.001
Gastrointestinal malignancy ^b	1250 (18.72)	3377 (42.37)	<0.001
Metastatic solid tumor	4451 (66.67)	10,090 (126.58)	<0.001
Acquired immunodeficiency syndrome	260 (3.89)	346 (4.34)	0.19
Neutropenia	909 (13.62)	1231 (15.44)	0.004
Solid organ transplantation (kidney, liver, heart, pancreas)	392 (5.87)	662 (8.31)	<0.001
Hematopoietic stem cell transplantation	29 (0.43)	106 (1.00)	<0.001
Incidence density of candidemia (per 1000 patient-days)	218 (0.34)	286 (0.41)	0.04

^a Any tumor is defined as any solid malignancy excluding gastrointestinal malignancy, metastatic malignancy, leukemia and lymphoma.

^b Gastrointestinal malignancy indicates malignancies involving any part of the following organs: esophagus, stomach, small or large intestines, and rectum.

Download English Version:

<https://daneshyari.com/en/article/3378219>

Download Persian Version:

<https://daneshyari.com/article/3378219>

[Daneshyari.com](https://daneshyari.com)